Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
about
MR Imaging of Hepatocellular Adenomas and Differential Diagnosis Dilemma.Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma.Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma.Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
P2860
Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatocellular MR contrast age ...... son to gadobenate dimeglumine.
@en
Hepatocellular MR contrast age ...... son to gadobenate dimeglumine.
@nl
type
label
Hepatocellular MR contrast age ...... son to gadobenate dimeglumine.
@en
Hepatocellular MR contrast age ...... son to gadobenate dimeglumine.
@nl
prefLabel
Hepatocellular MR contrast age ...... son to gadobenate dimeglumine.
@en
Hepatocellular MR contrast age ...... son to gadobenate dimeglumine.
@nl
P2093
P1476
Hepatocellular MR contrast age ...... ison to gadobenate dimeglumine
@en
P2093
Daniel T Boll
Elmar M Merkle
Sebastian Feuerlein
P304
P356
10.1016/J.EJRAD.2011.06.014
P577
2011-06-29T00:00:00Z